Pallas Health Review

Pallas Health is a service of Brentmoor, Inc. The current clinical disclosure says Pallas is the technology platform, Lion MD supplies clinical care, and CareValidate supports licensure verification, workflows, and prescription coordination.

The medical-team and clinical pages name Ana Lisa Carr, MD and Kelly Tenbrink, MD. Both NPI records were active when checked. Board-certification and unrestricted-license descriptions remain provider-stated because an NPI record does not verify those credentials.

Six current pharmacy partners are named: Belmar Pharmacy, Strive Pharmacy, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub, and Foothills Pharmacy. Assignment varies by medication, patient state, and current capacity.

Pallas says it accepts patients in all 50 states and Washington, D.C. Arkansas, Mississippi, New Mexico, North Dakota, Rhode Island, South Dakota, West Virginia, and Washington, D.C. are listed as requiring a synchronous visit before prescribing. Other states may use asynchronous review when clinically and legally appropriate.

An online intake starts the process. Treatment pages estimate about two minutes, while some state pages say about five. A licensed clinician reviews the history, may request audio or video, decides whether treatment is appropriate, and reviews progress and tolerability before refills.

Compounded semaglutide is $139 for the first month and then $597 every 12 weeks, described as $199 per month. Compounded tirzepatide is $179 initially and then $897 every 12 weeks, described as $299 per month. Introductory charges are excluded from durable card prices.

Pallas says the compounded GLP-1 price does not increase with a clinician-selected dose. Exact active-ingredient form, concentration, additives, vial quantity, syringe count, and beyond-use date are not public.

Brand-name cash prices are $1,349 per month for Wegovy, $1,069 for Zepbound, $1,299 for Ozempic, and $1,349 for Mounjaro. Wegovy and Zepbound have exact reusable catalog matches. Ozempic and Mounjaro remain narrative-only rather than being merged with a different manufacturer product.

NAD+ nasal spray is $79 for the first month and then $567 every 12 weeks, described as $189 per month. NAD+ injection is $89 initially and then $597 every 12 weeks, described as $199 per month. The routes remain separate cards.

Sermorelin injection is $89 for the first month and then $597 every 12 weeks, described as $199 per month. Pallas calls it a compounded subcutaneous injection with personalized dosing but does not publish strength, quantity, schedule, or laboratory protocol.

Skincare and women's hormone therapy are labeled coming soon. Neither is treated as an active therapy, regardless of future marketing or underlying site code.

Plan prices include clinician review, medication when prescribed, ongoing check-ins, dose adjustments, care-team messaging, the Pallas tracking app, and free shipping. Pallas says there is no separate membership or per-visit charge.

Checkout may collect a deposit up to $60 and save the payment method. If a clinician approves treatment, Pallas charges the remaining first-payment balance and anchors recurring billing to the approval date.

Clinician decline or cancellation before the clinical decision gets a full deposit refund. A patient in a live-visit jurisdiction who neither attends nor reschedules and abandons intake may have the deposit retained.

Cancellation is available in account settings or by contact and takes effect after the current billing period. An eligible customer-cancellation refund before pharmacy fulfillment may deduct third-party processing costs plus $5 per payment. Dispensed and shipped medication is generally nonrefundable.

Terms allow subscription price changes with at least 30 days' notice, effective with the next billing cycle after notice. The selected checkout still controls the current total and cadence.

Pallas is private-pay and does not bill insurance. Treatment pages say an itemized receipt is available for possible HSA or FSA reimbursement. Plan rules control eligibility and may require a letter of medical necessity.

Product pages say medication often arrives within about one week of approval, free and in plain unmarked packaging. The portal is advertised for shipment tracking. No universal cold-chain excursion, damage, reshipment, or replacement policy is public.

Technical questions use support@pallashealth.co with a stated one-business-day reply target. Membership and billing use hello@pallashealth.co. Phone support is available weekdays from 9 a.m. to 5 p.m. Eastern, and clinical messaging occurs in the portal.

Homepage wording about unlimited 24/7 support is interpreted as message access rather than live staffing because the published phone hours are limited and no round-the-clock response target is stated.

One clinical paragraph still describes the portal as launching with a July date that has passed, while the homepage presents portal features as active. This looks like stale copy, but a patient should confirm portal access during enrollment.

The privacy policy covers account, health, shipping, communication, usage, payment-status, AI-chat, meal-photo, voice-note, dose, symptom, weight, and mood data. It names clinical, pharmacy, database, AI, SMS, email, hosting, and payment vendors.

Pallas says AI requests omit direct identifiers and that data is not sold. App data can be deleted in settings or by request, subject to medical-record retention. Support publishes acknowledgment and completion targets for deletion requests.

The site says some public content may be AI-generated and disclaims its accuracy, completeness, and reliability. This is a reason to rely on specific terms and clinical disclosures rather than unsupported marketing prose.

Pallas displays a LegitScript certification link, but the linked checker did not provide an independently readable result during this pass. The certification is therefore recorded as provider-presented.

Compounded medications are not FDA approved and do not undergo FDA premarket review for safety, effectiveness, or quality. FDA's current GLP-1 guidance discusses dosing, salt-form, shipping-temperature, and multi-dose-vial concerns and limits appropriate compounding to patient need unmet by an approved drug.

FDA has warned sterile compounders to use drug-suitable NAD+ ingredients and described adverse events consistent with excess endotoxin exposure. This is general context, not evidence that a Pallas pharmacy violated the requirement.

Katalys program 1622 remains pending, with no issued tracking URL or compatible customer offer. The CTA uses the canonical site and no introductory-price banner. Affiliate payout and EPC did not affect the score or verdict.